Orthovita

Orthovita was a prominent medical technology company specializing in the development and commercialization of orthobiologics and biosurgery products. The company's portfolio was centered on synthetic bone graft substitutes and surgical hemostats designed to enhance clinical outcomes in orthopedic and neurosurgical procedures. Its flagship product, Vitoss, provided a scaffold for bone regeneration, while Vitagel served as a unique surgical hemostat and tissue sealant. Additionally, Orthovita developed Cortoss, an injectable bone augmentation material specifically for treating vertebral compression fractures. Headquartered in Malvern, Pennsylvania, the company established a significant global presence before its acquisition. In June 2011, Stryker Corporation acquired Orthovita for approximately $316 million to bolster its orthobiologics division.